World Psoriasis Day 2018: LEO Pharma urges people to connect with what’s under the skin of psoriasis to see the seriousness of the condition

New global campaign and report highlights the impact the condition can have on the wider wellbeing of the 125 million people living with the disease1

Ballerup, Denmark: October 29 marks the 14th annual World Psoriasis Day, LEO Pharma showcases a new global campaign and report in recognition of the seriousness of psoriasis and the underestimation of the true burden of living with the disease.2 LEO Pharma are advocating for better treatment options and improved access to care with launch of ‘I’m more than my skin’; a campaign illustrating the serious, multifaceted nature of psoriasis. ‘I’m more than my skin’ underscores the ‘Pso Serious’ theme of World Psoriasis Day 2018, focusing on the debilitating potential of the disease.

Psoriasis is a serious, lifelong condition that primarily affects the skin, but also impacts emotional, psychological and physical health.2,3 The disease can be disabling and stigmatising, and it carries with it a number of associated diseases (known as comorbidities).2 People with psoriasis are over 50% more likely to be clinically obese than the general population,4 putting them at increased risk of serious health complications such as diabetes, heart disease, stroke and some cancers.5

The need for greater awareness and optimal treatment is reinforced by the newly issued World Psoriasis Happiness Report, highlighting that people with psoriasis are more likely to suffer from serious life limiting conditions than the general population. Specifically, the new report shows the impact the condition can have on wider wellbeing by uncovering the links between comorbidities and happiness levels. Key findings include:

  • Women with the disease more often suffer from back pain, joint diseases, ulcers and stomach diseases, while men are more prone to high blood pressure and heart and vascular diseases.6
  • Depression or other mental disorders are amongst the most common comorbidities for people living with psoriasis; with women being almost twice as likely to suffer from a mental health condition as men.6
  • Loneliness was found to be one of the strongest predictor of comorbidities: while one in five people with psoriasis reported feeling lonely, the number almost doubled in people living with three different comorbidities.6

Despite recent advancements in treatments, and the World Health Organization’s recognition of psoriasis as an area of focus, levels of care around the globe are not uniform and can fall short, leaving millions suffering needlessly.2 Crucially, it is not yet common practice for all healthcare providers to regularly screen for comorbidities or monitor and support an individual’s mental health and wider well being.

Psoriasis may look like ‘just a skin disease’, but it is so much more; just as those living with psoriasis, are so much more than the condition itself. It is LEO Pharma’s mission to help people achieve healthy skin; but tackling the condition of someone’s skin is just the first step. It LEO Pharma’s hope that the ‘I’m more than my skin’ campaign will help to educate people about the true physical and emotional impact of psoriasis, and justify why more is needed: more understanding, but also more access to treatment options that take the whole person into consideration.

For more information on the ‘I’m more than my skin’ campaign and how LEO Pharma is supporting World Psoriasis Day 2018, please visit www.immorethanmyskin.com


- ENDS-
 


NOTES TO EDITORS

The World Psoriasis Happiness Report

Developed by the Happiness Research Institute, in partnership with the LEO Innovation Lab, an independent unit of LEO Pharma, the World Psoriasis Happiness Report provides an analysis of findings from online surveys completed by more than 6,500 people in 14 countries who live with psoriasis – a serious, chronic autoimmune disease.

The report can be viewed in full at https://psoriasishappiness.report.

About LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 130 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,200 people worldwide.

Facebook: www.facebook.com/LEOPharmaAS
LinkedIn: www.linkedin.com/company/leo-pharma
Twitter: http://www.twitter.com/LEOhealthyskin
YouTube: www.youtube.com/leopharmaglobal 

References

  1. The International Federation of Psoriasis Associations. Available at https://ifpa-pso.com/ (Accessed July 2018)
  2. World Health Organization (WHO). Global Report on Psoriasis. Available at: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf (Accessed July 2018).
  3. Dermatology Life Quality Index. http://sites.cardiff.ac.uk/dermatology/files/2014/07/DLQI.pdf (Accessed August 2018).
  4. Armstrong et al. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012;2(12):e54.
  5. European Association for the Study of Obesity. About obesity. Available at: http://easo.org/media-portal/obesity-facts-figures/about-obesity/ (Accessed August 2018)
  6. World Psoriasis Happiness Report 2018. Available at: https://psoriasishappiness.report/

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.